2023
DOI: 10.1186/s13063-022-07038-6
|View full text |Cite
|
Sign up to set email alerts
|

Biologic Abatement and Capturing Kids’ Outcomes and Flare Frequency in Juvenile Spondyloarthritis (BACK-OFF JSpA): study protocol for a randomized pragmatic trial

Abstract: Background The effectiveness of biologic therapies, primarily tumor necrosis factor inhibitors (TNFi), for children with spondyloarthritis (SpA) has made inactive disease a realistic patient outcome. However, biologic therapies are costly, primarily delivered by subcutaneous or intravenous route, and have non-trivial side effects. Many patients and families want to know if biologic medications can be discontinued after inactive disease is achieved. It remains unclear whether medication dose sho… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
2

Relationship

1
1

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 26 publications
0
2
0
Order By: Relevance
“…The Biologic Abatement and Capturing Kids’ Outcomes and Flare Frequency in Juvenile SpA (BACK-OFF JSpA) trial is a currently ongoing multicenter randomized pragmatic trial evaluating efficacy of de-escalation strategies for TNFi among JSpA patients who have achieved sustained inactive disease for at least 6 months [48 ▪ ].…”
Section: Treatment De-escalationmentioning
confidence: 99%
“…The Biologic Abatement and Capturing Kids’ Outcomes and Flare Frequency in Juvenile SpA (BACK-OFF JSpA) trial is a currently ongoing multicenter randomized pragmatic trial evaluating efficacy of de-escalation strategies for TNFi among JSpA patients who have achieved sustained inactive disease for at least 6 months [48 ▪ ].…”
Section: Treatment De-escalationmentioning
confidence: 99%
“…In the Disease Recapture in JIA study, of ERA patients who withdrew mediation, 17 of 35 (49%) and 26 of 36 (72%) achieved inactive disease by 6 and 12 months, respectively, as defined by physician global assessment (PGA) of disease activity <1 and active joint count of 0 [19 ▪▪ ]. To address the paucity of data in ERA, there is an ongoing multicenter pragmatic trial comparing response to continuing, spacing, or discontinuing TNFi therapy in patients with CID [25 ▪ ].…”
Section: Enthesitis Related Arthritismentioning
confidence: 99%